Invivyd (IVVD) Share-based Compensation (2021 - 2025)
Invivyd (IVVD) reported Share-based Compensation of $2.6 million for Q4 2025, down 16.13% on a YoY basis from $3.1 million in Q4 2024, and down 16.56% quarter-over-quarter from $3.1 million in Q3 2025.
Invivyd (IVVD) Share-based Compensation (2021 - 2025) Analysis & Trends
Invivyd has reported Share-based Compensation for 5 years, with the latest figure at $2.6 million in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation fell 16.13% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $11.6 million (down 41.17% YoY), and the FY2025 full-year result was $11.6 million, down 41.16% from the prior year.
- Share-based Compensation for Q4 2025 stood at $2.6 million, down from $3.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $8.5 million in Q2 2024, with the low at $587000.0 in Q1 2021.
- Historically, Share-based Compensation has averaged $4.5 million across 5 years, with a median of $4.3 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 237.82% — and 2025, when it tumbled 62.54%.
- Invivyd's Share-based Compensation stood at $7.9 million in 2021, then declined by 24.83% to $5.9 million in 2022, then retreated by 26.44% to $4.3 million in 2023, then declined by 29.63% to $3.1 million in 2024, then declined by 16.13% to $2.6 million in 2025.
- The last three Share-based Compensation figures came in at $2.6 million (Q4 2025), $3.1 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 2.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.56 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 3.07 Mn |
| Sep 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Sep 30, 2023 | 4.26 Mn |
| Sep 30, 2023 | 4.26 Mn |